Free shipping on orders over $99Ships to the US and Canada New: dosage, calculator and shelf life for all 46 peptides →

Pinealon dosage and protocol

Pinealon dosage on this page comes only from published human studies, each linked to its source, with how it was given and to whom. Pinealon is a synthetic tripeptide, Glu-Asp-Arg (EDR), from the Khavinson group of short peptide bioregulators. It is studied for effects on nerve cells.

Human study dosesNot an approved drug

What Pinealon dosage is on record?

100 mcg in human studies

1 dose on record from published human research (1). How it was given: by mouth. None of these were stated as injections under the skin or into a muscle.

Checked 11 Nov 2026 against labels, PubMed and the US and Canadian regulators.

What Pinealon is

Pinealon is a synthetic tripeptide, Glu-Asp-Arg (EDR), from the Khavinson group of short peptide bioregulators. It is studied for effects on nerve cells. (2)

Other names and codes used in the research: EDR, EDR peptide, Glu-Asp-Arg, glutamyl-asparagin-arginine.

How Pinealon works

Pinealon is the tripeptide EDR, and the published account of where it came from is specific: it was cut down from cortexin, a polypeptide preparation made from calf brain cortex that is used clinically in Russia. (3)

Two short peptides were synthesised from that preparation, EDR being one of them, and both are described as carrying the neuroprotective activity. (3)

The proposed mechanism is physical contact with DNA. In a physics laboratory study using spectroscopy, nuclear magnetic resonance and molecular dynamics, the peptide was seen to slip part way into the wide groove of the DNA helix and touch guanine bases. (4)

That same work found the interaction depends on the salt around it: magnesium ions shield DNA's negative charge and make the peptide bind more readily, which matters for any claim about what happens inside a living cell. (4)

A separate Moscow laboratory labelled the peptide with a fluorescent tag and watched it enter human cells in culture, including the nucleus and nucleolus, which is the step every gene-level claim depends on. (5)

In the same experiments the binding was not indiscriminate. The peptides told different DNA sequences apart and even responded to whether a cytosine base carried a methyl mark. (5)

Pinealon preferred stretches of DNA built on the CNG pattern, which is where cytosine methylation happens in higher organisms. That is the chain of reasoning behind calling it an epigenetic regulator. (5)

DNA is not the only proposed target. In fluorescence work with wheat histones, the peptide bound the histone proteins that package DNA, alongside five related short peptides. (6)

The authors of that work read histone binding as the control point: a peptide sitting on a histone tail could open or close a stretch of chromatin and so change which genes are available. (6)

One specific gene has been named. In aging brain cortex cell cultures the peptide raised serotonin production, and docking matched it to a six-letter sequence in the gene for the enzyme that makes serotonin. (7)

Against the popular shorthand that it is an antioxidant, a laboratory study of this peptide family found no direct antioxidant action at all. What it found was an indirect effect on the structure of blood lipoproteins. (8)

Where Pinealon came from

The peptide was built by the same St. Petersburg programme that produced the pineal and thymus preparations, and the 2008 Russian papers place it in a group tested together: vilon, epitalon, vesugen and pinealon, screened side by side for resistance to low oxygen. (9)

In the Russian literature it is classed as a nerve-protection product, in a second tier below the older extract preparations. A 2013 review sets the two tiers out: polypeptide complexes such as cortexin and cerebrolysin, and short peptides such as semax, cortagen and pinealon. (10)

As of 2024 the originating institute still presents it as a candidate for Alzheimer's disease, listed among a handful of short peptides described as acting on several targets at once. (11)

Pinealon dosage on record

Every Pinealon dosage below comes from a product label or a published human study. The grey line under each dose is the source's own wording, so you can check it. Doses from different studies are not interchangeable: look at how it was given, to whom and for how long.

DoseTypeHow oftenHow longWho
100 mcg per capsuleRussian study of railway locomotive crews (design, phase and number of people not stated in the abstract); capsules by mouth, not injected. The abstract writes the unit as mkg, meaning micrograms.Source text: “1 capsule containing 100 mkg of Pinealon 2 times a day”Human studyone capsule twice a daytwo weeksworkers of locomotive crews; the abstract gives no number (1)

How to reconstitute Pinealon

Pinealon comes as a dry powder (20 mg vials). Reconstituting it means adding bacteriostatic water so it can be drawn into a syringe. The water does not change how much Pinealon is in the vial, only how strong each mL is, so it decides how many syringe units a dose takes.

VialWaterStrengthWhat 10 units holdsDoses between 5 and 100 units
20 mg1 mL20 mg/mL2 mg in every 10 units1 mg to 20 mg
20 mg2 mL10 mg/mL1 mg in every 10 units500 mcg to 10 mg
20 mg3 mL6.667 mg/mL667 mcg in every 10 units333 mcg to 6.67 mg

The last column is the range of doses that land between the 5 unit mark (small marks are hard to read) and the 100 unit mark of a 1 mL U-100 syringe for that mix. All of it is arithmetic.

Reconstitution steps

  1. Wash your hands, work in a clean area and set out the Pinealon vial, bacteriostatic water, a sterile syringe, alcohol pads and a sharps container (13).
  2. Check the vial and the water: right product, in date, intact cap (13).
  3. Wipe both rubber tops with an alcohol pad and let them dry (13).
  4. Draw the water amount you picked from the table into the syringe.
  5. Push the needle through the Pinealon vial stopper and let the water in slowly.
  6. Move the vial in a circle until the powder is fully dissolved. Do not shake it (14).
  7. Check the liquid. MedlinePlus says not to use it if it has changed color, has floating pieces or is cloudy (13).
  8. Write the date you mixed it on the vial (13), and note the water amount so every later draw uses the same numbers.

After mixing

No published storage data exists for mixed Pinealon; the bacteriostatic water label says not to store a mixed drug unless its maker says you can (12).

For any other vial size, water amount or dose, use the Pinealon reconstitution calculator.

Pinealon dosage and half-life

No half-life, blood level or bioavailability figure exists for this peptide in people. The nearest thing to absorption data is the fluorescent-tag work showing a short peptide can cross into an animal cell and reach the nucleus. (5)

How a three amino acid peptide would get into cells at all is answered by modelling rather than measurement: the peptide carriers of the PEPT family are described as handling two and three amino acid peptides. (15)

Stability in the body has not been measured either. The published chemistry is about binding instead: the peptide's grip on DNA changes with the ions around it, so the salt and magnesium of real tissue would matter. (4)

What the Pinealon research found

In people

  • Small human studyIn railway locomotive crews, two weeks of capsules was reported to improve biological age measures. The abstract gives no numbers, no group sizes and no placebo group. (1)Source text: “Pinealon application has improved parameters of biological age and indicators determining the effectiveness of adaptive reactions.”
  • Small human studyIn 32 people aged 41 to 83 with several chronic illnesses, Pinealon and a second peptide, Vesugen, were reported to slow aging measures; Vesugen did better. The abstract gives no dose. (16)Source text: “Vesugen has demonstrated more visible geroprophylactic effect than Pinealon.”
  • Small human studyIn a comparison of anti-aging methods in 110 people, the largest change in biological age measures came when Pinealon and Vesugen were used together, so the result cannot be credited to Pinealon alone. (17)Source text: “The most pronounced positive impact on indicators of biological age were detected during the combined use of these two Oligopeptide complexes.”
  • Small human studyIn a study of long-distance truck drivers, peptide use was reported to improve measures of mental strain, with the best result again from Pinealon combined with Vesugen. (18)Source text: “The best effect was obtained in case of combined application of several cytogens (pinealon and vezugen)”

In animals and in the lab

These results come from animals or cells. They show what researchers are looking at, not what Pinealon does in people.

  • Lab studyIn cultured cells under oxidative stress, Pinealon limited the build-up of reactive oxygen species. (2)Source text: “demonstrates dose-dependent restriction of reactive oxygen species (ROS) accumulation in cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells”
  • Animal studyGiven to pregnant rats with raised homocysteine, it improved learning and spatial orientation in their offspring. (19)Source text: “the administration of pinealon to pregnant rats loaded with methionine improved their offspring spatial orientation and learning ability”
  • Animal studyIn a mouse model of Alzheimer's disease, the EDR peptide prevented loss of dendritic spines. (20)Source text: “KED and EDR peptides prevented dendritic spine loss in 5xFAD-M mice.”
  • Lab studyIn neurons made in the lab from skin cells of elderly donors, the EDR peptide reduced oxidative DNA damage. (21)Source text: “EDR peptide reduces oxidative DNA damage in induced neurons derived from elderly donor fibroblasts.”
  • Lab studyIn mouse hippocampal nerve cells poisoned with amyloid, the peptide at 200 nanograms per millilitre raised the count of mushroom-shaped spines, the connection points used for memory, by 71 percent and brought them back to normal. (22)Source text: “peptide EDR (200 ng/ml) under conditions of amyloid synaptotoxicity (a model of Alzheimer's disease) increased the number of mushroom spines by 71%”
  • Lab studyIn the same dish experiment a sister peptide, KED, managed 20 percent on the same measure, so this peptide was the stronger of the two tested. (22)Source text: “tripeptide KED (200 ng/ml) increased the number of mushroom spines in hippocampal neurons by 20%”
  • Lab studyThe authors' own conclusion from that result was a recommendation for further experimental study, not for use. Nine years on, no human trial has followed. (22)Source text: “Tripeptide EDR can be recommended for further experimental study as a candidate neuroprotective agent for prevention and treatment of Alzheimer's disease.”
  • Lab studyIn 2025 an Institute of Cytology group turned fetal stem cells into cortical nerve cells and added this peptide with two others to see whether it slowed cell aging in the new neurons. (23)Source text: “The goal of this study was to assess the effect of KED, EDR, and AEDG short peptides in stimulating the transdifferentiation of fetal MSCs into induced neuronal cells”
  • Lab studyThe aging markers did come down in that study, but the credit went to the other two peptides: the 15 percent drop in p21 and the fall in the senescence enzyme were reported for AEDG and KED. (23)Source text: “the application of AEDG and KED short peptides at the end of the transdifferentiation process decreases the expression of the cell cycle marker p21 by 15%”
  • Lab studyTwo other markers in that experiment did not budge for any of the three peptides, which is the kind of mixed result that rarely makes it into product copy. (23)Source text: “short peptides did not affect the expression levels of TUj-1 and LaminB1”
  • Lab studyIn cultures of the pineal gland itself, the gland this peptide is named after, it did nothing measurable: cell renewal and the secretion marker were raised by a different peptide, and the cell death marker was unchanged by pinealon. (24)Source text: “These peptides as well as Glu-Asp-Arg and Lys-Glu do not affect the expression of apoptosis marker AIF”
  • Lab studyIn that pineal gland experiment the growth marker Ki-67 responded to the tetrapeptide AEDG and to KED, and the secretion factor only to AEDG. (24)Source text: “The synthesis of transcription factor CGRP by pinealocytes was stimulated only by Ala-Glu-Asp-Gly.”
  • Lab studyIn aging cultures of brain cortex cells, the peptide raised production of serotonin, the signal most often invoked for mood and sleep claims. This is cells in a dish, not people. (7)Source text: “Peptides Glu-Asp-Arg and Lys-Glu-Asp stimulate serotonin expression in aging cultures of brain cortex cells.”
  • Animal studyAcross a four-peptide screen in rats exposed to low-pressure oxygen starvation, this one came out strongest. (9)Source text: “Pinealon (Glu-Asp-Arg) has the most pronounced effect among them.”
  • Animal studyThe authors put that oxygen-starvation effect down to the cell's own antioxidant enzymes being switched on rather than to the peptide mopping up free radicals itself. (9)Source text: “It is based not so much on the inhibition of ROS increase in cells in response to stress as on stimulation of internal antioxidative enzyme system”
  • Animal studyA second proposed route in that work was damping the glutamate signal that kills nerve cells under stress, which the authors raise as a possibility rather than a finding. (9)Source text: “possibly limiting the excitotoxic effect of N-methyl-D-aspartate”
  • Animal studyIn old rats learning a water maze, the peptide beat the calf-brain extract cortexin on learning in both young and old animals. (25)Source text: “Pinealon has prevalent positive effect on learning of both young and old animals in the Morris labyrinth compared to cortexin.”
  • Animal studyOn brain chemistry in 18-month-old rats under low oxygen and cooling, the comparison went the other way: the extract did more to free radical processes and to the cell death enzyme than the peptide did. (26)Source text: “Cortexin shows a more pronounced effect on free radical processes and caspase 3 activity in brain than Pinealon.”
  • Animal studyIn old rats with sudden oxygen starvation, the peptide was reported to push new nerve cell formation up and brain inflammation back toward normal levels. (27)Source text: “in hypoxia of brain conditions Pinealon forwards the increase of the neurogenesis and the decrease neuroinflammatory reactions to a reference level”
  • Animal studyIn old rats whose neck arteries were clamped, giving short peptides beforehand improved how many animals survived the procedure. (28)Source text: “It is shown that introduction of short peptides promotes a survival rate of the animals that have modeled occlusion of carotid arteries.”
  • Animal studyThe behaviour side of that same stroke experiment went the wrong way for this peptide: animals given it before the clamping were sleepier and did less exploring, less goal-seeking and less moving about. (28)Source text: “Under Pinealon before occlusion of carotid arteries, behavioral dream has been increased and a position-finding behavior, a motivational behavior and a motor performance have been reduced.”
  • Animal studyIn the same study the cell death enzyme caspase-3 rose moderately in the brains of peptide-treated animals, both in the stroke model and in the sham-operated controls. That is the opposite of the protective story usually told about it. (28)Source text: “At introduction of Pinealon activity of caspase-3 moderately raises in false-operated animals and in a model of occlusion of carotid arteries.”
  • Lab studyIn laboratory tests this peptide family stiffened red blood cell membranes against bursting in dilute salt solution, one of the few direct physical effects measured for it. (8)Source text: “The short peptides increase stability of red blood cell membranes toward osmotic hemolysis.”
  • Lab studyThe same tests found the peptides raised the resting level of reactive oxygen species inside cells, so the antioxidant label does not fit the measurements cleanly. (8)Source text: “They also elevate the stationary level of intracellular reactive oxygen species”
  • Lab studyComputer docking of 26 short peptides against the body's own amino acid and peptide carriers put EDR among the handful with the best fit, a group defined by a negative charge at one end. (29)Source text: “Peptides ED, DS, DR, EDR, EDG, AEDR, AEDL, KEDP, and KEDG, and peptoids DS7 and KE17 with negatively charged Asp- or Glu- amino acid residues at the N-terminus”

Pinealon dosage and side effects

What labels and human studies report. A short or small study can miss rare side effects, so an empty list is not proof of safety.

  • The study in 32 people found a fall in a blood stem cell marker, which the authors read as inhibition of blood cell formation. (16)
  • The same study found pro-oxidant activity, the opposite of the antioxidant effect seen in cell culture. (16)
  • The comparison in 110 people rated the peptide preparations and massage as the safest of the methods tested, judged by blood tests and clinical condition. No independent human safety study was found. (17)

Animal safety findings

These come from animal studies, not people, but they are the only safety data on record for some outcomes.

  • In cultures of the pineal gland itself, the gland this peptide is named after, it did nothing measurable: cell renewal and the secretion marker were raised by a different peptide, and the cell death marker was unchanged by pinealon. (24)
  • On brain chemistry in 18-month-old rats under low oxygen and cooling, the comparison went the other way: the extract did more to free radical processes and to the cell death enzyme than the peptide did. (26)
  • In old rats whose neck arteries were clamped, giving short peptides beforehand improved how many animals survived the procedure. (28)
  • In the same study the cell death enzyme caspase-3 rose moderately in the brains of peptide-treated animals, both in the stroke model and in the sham-operated controls. That is the opposite of the protective story usually told about it. (28)

Injecting under the skin

General steps for an injection under the skin, from MedlinePlus (30). Labels for approved products give their own instructions, which come first.

  1. Pick a site: the belly (below the ribs, above the hip bones and at least 2 inches from the belly button), the outer upper thigh, or the back or side of the upper arm.
  2. Move to a new spot each time, at least 1 inch from the last one. MedlinePlus says this keeps the skin healthy and helps the body absorb the medicine.
  3. Wash your hands with soap and running water for at least 1 minute, dry them, then clean the skin with an alcohol pad and let it dry.
  4. Pinch about an inch of skin and fat, put the needle in quickly at 90 degrees (45 degrees if there is little fat), let go of the skin and push the plunger all the way.
  5. Pull the needle out, put it straight into a sharps container, and press clean gauze on the spot for a few seconds. Never reuse a needle or syringe.
  6. Some soreness is expected. MedlinePlus says to contact a health care provider for signs of infection such as redness, swelling, red streaks or fever.

To draw the right amount, use the Pinealon calculator and the drawing steps on that page.

Is Pinealon banned in sport?

The anti-doping position has moved since this compound's fact file was written. On the list in force from 1 January 2027, peptides are named as a class in S0, the category prohibited at all times. (31)

S0 is defined by lack of approval anywhere in the world, which is exactly this peptide's regulatory position. (31)

Pinealon is not among the peptides listed by name in the advisory, and the agency states that the list is not exhaustive and that unlisted peptides may still be banned. (31)

The agency also warns that products sold for these purposes carry a health risk on top of the sanction risk. (31)

Is Pinealon legal in the US and Canada?

United States: Not FDA approved. No Pinealon product or label was found in Drugs@FDA. (32)
openFDA searches of Drugs@FDA and of drug labels for pinealon returned no match on 2026-10-11. Pinealon is not named on FDA's page of bulk substances that may present significant safety risks (S12, page current as of 2026-04-22).
Canada: No Pinealon product is in Health Canada's Drug Product Database, and Health Canada lists Pinealon among unauthorized injectable peptide drugs seized from an online seller. (33)
Advisory last updated 2025-08-01. Drug Product Database ingredient searches for pinealon and glu-asp-arg returned 0 records on 2026-10-11 (S11).

What is still unknown

  • Human data are thin: four small Russian studies, none described as placebo-controlled, published in one journal. Three of them tested Pinealon alongside a second peptide, Vesugen.
  • The one human dose on record was taken by mouth, 100 mcg twice a day. No published study injected Pinealon in people, so injected doses in circulation have no trial behind them.
  • The reported injected range is 5 to 25 times the daily amount used in that study, and by a different route.
  • One human study found signs of reduced blood cell formation and pro-oxidant activity (S2). Its authors still recommended the peptide.
  • The nerve cell and memory findings are from cell culture, rats and mice, and come mostly from the group that developed the peptide (S5, S6, S7, S8).
  • Not an approved medicine in the US or Canada as of the check date. Health Canada lists Pinealon among unauthorized injectable peptide drugs seized from an online seller (S13).
  • No human study of Pinealon given by injection with a stated dose. The only human dose found is 100 mcg by mouth twice a day for two weeks (S1).
  • The other three human papers (S2, S3, S4) give no dose in their abstracts. All four are in Russian and only their English abstracts were read.
  • No randomized, placebo-controlled trial. None of the human abstracts describes a placebo group or blinding.
  • The study behind the line that the peptide improves memory in elderly patients, which appears in a 2020 review by its originators (S7).
  • No human half-life or other pharmacokinetic figure.
  • No trial registered on ClinicalTrials.gov: a search for pinealon as the intervention returned no studies.
  • No approved label in the US or Canadian sources searched, so no official dose, contraindications or storage instructions.
  • Not named on the WADA Prohibited List (page checked 2026-10-11, S14). The list has an open class, S0, for substances with no current approval by any governmental health authority; whether it applies to this compound was not determined here.
  • No new human study has appeared. Everything added here is cell culture, rats, mice or computer modelling, and the four small Russian human papers in the existing file are still the whole human record.
  • No human pharmacokinetic figure of any kind: no half-life, no blood level, no bioavailability, by any route.
  • No toxicity programme was found: no acute or repeat-dose study, no genotoxicity test, no reproductive study.
  • The memory and nerve claims rest on a dish: the strongest single result is a 71 percent rise in spine counts in cultured mouse neurons (X1), with no animal behaviour or patient outcome to match it.
  • Results point both ways in rats. The same peptide improved maze learning (X12) but left animals sleepier and less active after a stroke model and raised a cell death enzyme in their brains (X11).
  • In the gland it is named after, it had no measurable effect in culture; the effects there belonged to other peptides in the family (X14).
  • FDA's compounding advisory committee reviewed seven peptides in July 2026 and pinealon was not one of them, so no US regulator assessment of this substance exists to cite.
  • No source fetched here shows pinealon registered as a medicine in Russia or anywhere else. Cortexin, the extract it was derived from, is the preparation described as clinically approved (X6).
  • The WADA prohibited list PDF itself could not be opened in this session (the site returned an empty response), so the sport status is taken from the US anti-doping agency's advisory about that list.

Pinealon dosage questions

What Pinealon dosage was used in human studies?

100 mcg per capsule, one capsule twice a day. Each is listed with its study on this page.

How often was Pinealon given?

In the sources on this page: one capsule twice a day.

How long were Pinealon courses?

In the sources on this page: two weeks.

Is Pinealon approved?

Not FDA approved. No Pinealon product or label was found in Drugs@FDA. No Pinealon product is in Health Canada's Drug Product Database, and Health Canada lists Pinealon among unauthorized injectable peptide drugs seized from an online seller.

What side effects of Pinealon have been reported?

The study in 32 people found a fall in a blood stem cell marker, which the authors read as inhibition of blood cell formation. The same study found pro-oxidant activity, the opposite of the antioxidant effect seen in cell culture.

Is Pinealon banned in sport?

The anti-doping position has moved since this compound's fact file was written. On the list in force from 1 January 2027, peptides are named as a class in S0, the category prohibited at all times.

How many units of Pinealon do I draw?

Use the Pinealon calculator: pick your vial, water and dose, and it gives the units on a U-100 insulin syringe.

Sources

  1. Nazimko VA et al. [Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades]. Adv Gerontol 2012. PubMed 22708445
  2. Khavinson V et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res 2011. PubMed 21978084
  3. Kuznik BI et al. [Epigenetic Mechanisms of Peptide-Driven Regulation and Neuroprotective Protein FKBP1b]. Mol Biol (Mosk) 2019. PubMed 31099784
  4. Silanteva IA et al. Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction. J Phys Chem B 2019. PubMed 30762356
  5. Fedoreyeva LI et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc) 2011. PubMed 22117547
  6. Fedoreyeva LI et al. Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides. Biochemistry (Mosc) 2013. PubMed 23581987
  7. Khavinson VKh et al. Short peptides stimulate serotonin expression in cells of brain cortex. Bull Exp Biol Med 2014. PubMed 24909721
  8. Kozina LS et al. [Biological activity of regulatory peptides in model experiments in vitro]. Adv Gerontol 2008. PubMed 18546826
  9. Kozina LS et al. [Investigation of antihypoxic properties of short peptides]. Adv Gerontol 2008. PubMed 18546825
  10. Umnov RS et al. [Neuroprotective effects of peptides bioregulators in people of various age]. Adv Gerontol 2013. PubMed 24738258
  11. Ilina AR et al. [Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.]. Adv Gerontol 2024. PubMed 38944767
  12. Bacteriostatic Water for Injection, USP (Hospira) label. DailyMed
  13. MedlinePlus, Drawing medicine out of a vial (reviewed 14 Jan 2026). medlineplus.gov
  14. Egrifta WR (tesamorelin) US prescribing information, section 2.2. DailyMed
  15. Khavinson V et al. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Int J Mol Sci 2022. PubMed 35887081
  16. Meshchaninov VN et al. [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]. Adv Gerontol 2015. PubMed 26390612
  17. Myakotnykh VS et al. [Comparative analysis of different methods of geroprotective]. Adv Gerontol 2016. PubMed 28539017
  18. Bashkireva AS et al. [The peptide correction of neurotic disorders among professional truck-drivers]. Adv Gerontol 2012. PubMed 23734521
  19. Arutjunyan A et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med 2012. PubMed 22567179
  20. Khavinson V et al. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel) 2021. PubMed 34071923
  21. Kraskovskaya N et al. Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. Int J Mol Sci 2024. PubMed 39518916
  22. Kraskovskaya NA et al. Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease. Bull Exp Biol Med 2017. PubMed 28853087
  23. Sakhenberg E et al. The Influence of Short Peptides on Cell Senescence and Neuronal Differentiation. Curr Issues Mol Biol 2025. PubMed 41020860
  24. Khavinson VKh et al. Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture. Bull Exp Biol Med 2011. PubMed 22803060
  25. Mendzheritski AM et al. [Effect of peptide geroprotectors on the navigation system learning and caspase-3 in brain structures in rats of different age]. Adv Gerontol 2013. PubMed 28976148
  26. Mendzheritsky AM et al. [Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia]. Adv Gerontol 2015. PubMed 28509493
  27. Mendzheritskii AM et al. [Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon]. Adv Gerontol 2014. PubMed 25051764
  28. Mendzheritskii AM et al. [Effects of introduction of short peptides before carotid artery occlusion on behaviour and caspase-3 activity in the brain of old rats]. Adv Gerontol 2011. PubMed 21809624
  29. Khavinson VK et al. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023. PubMed 36979488
  30. MedlinePlus, Subcutaneous (SQ) injections. medlineplus.gov
  31. Athlete Advisory: What's New on the 2027 WADA Prohibited List?. 2026. usada.org
  32. Drugs@FDA and drug label searches via openFDA for pinealon (no match). 2026. api.fda.gov
  33. Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks. 2025. recalls-rappels.canada.ca

Facts checked 11 Oct 2026 and 11 Nov 2026 against the sources above. This page reports what labels and published studies used. It is not medical advice: talk to a licensed prescriber before you start, stop or change anything.

Keep going